Prader-Willi Syndrome
120
17
22
61
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
20 trials with published results (17%)
Research Maturity
61 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.7%
14 terminated out of 120 trials
81.3%
-5.3% vs benchmark
23%
27 trials in Phase 3/4
33%
20 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 61 completed trials
Clinical Trials (120)
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Parent and Infant Inter(X)Action Intervention (PIXI)
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
Early Check: Expanded Screening in Newborns
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Impact of Bright Light Therapy on Prader-Willi Syndrome
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
PWS European Blood Bank for Infants and Controls From 0 to 48 Months
A Study of Pitolisant in Participants With Prader-Willi Syndrome
Physical Activity and Community EmPOWERment Project
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
Institutional Registry of Rare Diseases